Relafen 750, chemically known as naproxen, represents a noteworthy case study from a pharmaceutical pharmacy standpoint. This exhibits its medicinal effect primarily by inhibiting the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby limiting prostaglandin production . The targeted inhibition of COX-2, compared to older NSAIDs,